---
schema_version: "secwatch.filing_event.v1"
accession: "0001062822-26-000047"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:17:51.103828+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lexicon Q4 net loss narrows to $15.5M; cash strengthened with $106.7M added in Feb 2026

## Summary
- Q4 net loss $15.5M ($0.04/share) vs $33.8M loss ($0.09/share) in Q4 2024; full-year loss $50.3M.
- Q4 revenue $5.5M including $4.3M licensing from Novo Nordisk and $1.1M INPEFA sales.
- Cash, investments, restricted cash $125.2M at Dec 31, 2025; $96.7M capital raise + $10M Novo milestone in Feb 2026.
- SONATA-HCM enrollment >50% of 500 patients; on track for mid-2026 completion and Q1 2027 topline.
- NDA resubmission for ZYNQUISTA in T1D on track for 2026; positive End-of-Phase 2 meeting for pilavapadin.

## SEC filing metadata
- accession: 0001062822-26-000047
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000047/0001062822-26-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000047/lxrx-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062822-26-000047
- JSON: https://secwatch.observer/filing/0001062822-26-000047.json
- Plain text: https://secwatch.observer/filing/0001062822-26-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.